Clinical trial
Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders…
NCT00005606 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00005606 |
|---|---|
| Title | Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation |
| Official title | Adoptive Immunotherapy of Epstein Barr Virus Induced Lymhoproliferative Disease. A Comparison of Allogeneic and Autologous Lymphocyte Responses ex Vivo and Use of Highly Selected Reactive Cells as an Alternative to Chemotherapy in Vivo. |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological |
| Interventions | allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes, autologous Epstein-Barr virus-specific cytotoxic T lymphocytes |
| Start date | Feb 1, 2000 |
| Primary completion | Sep 1, 2003 |
| Completion | Sep 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: